SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Ann Richards — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAnn Richards
Date of birth1933-09-01
IdentifiersMRN HR-ML019-SYN-TD; SSN (made up) 000-19-3381
Document date1997-03-10
AuthorRosalind Teague, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week bone health review. [S]

History of Present Illness

Ms. Richards returns four weeks after her intake visit. She takes vitamin D3 1971 units every day. She has added yogurt, cheese, and calcium-fortified orange juice, and her three-day food record shows about 1200 mg of calcium a day. She keeps walking and lifting weights and has had no falls. She did not collect the 24-hour urine sample before this visit because she was traveling for three weeks. She saw the endocrinologist this morning. Her balance and strength program with the physical therapist starts next week, and she has a routine dental examination booked next month. She has had no alcohol and no cravings. [S]

ElementDetail
Calcium intakeAbout 1200 mg a day from food by three-day record
Vitamin DD3 1971 units daily, no missed doses
FallsNone
Pending tests24-hour urine calcium not yet collected
RecoveryNo alcohol; no cravings

Review of Systems

SystemResultFinding
MusculoskeletalNegativeNo back pain, new bone pain, or fracture; the healed hand is not painful
NeurologicalNegativeNo dizziness or unsteadiness
GastrointestinalNegativeNo constipation since adding dairy foods
PsychiatricNegativeMood good; no cravings; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet dailyOne tablet by mouth dailyOral route1997-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1997-03-10Body height164cmS
1997-03-10Body weight66.2kgS
1997-03-10Body mass index (BMI) [Ratio]24.6kg/m2S
1997-03-10Systolic blood pressure122mm[Hg]S
1997-03-10Diastolic blood pressure74mm[Hg]S
1997-03-10Heart rate70/minS
1997-03-10Respiratory rate14/minS
1997-03-10Body temperature36.7CelS
1997-03-10Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1997-03-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell and animated; weight 66.2 kg
SpineNo tenderness or kyphosis; occiput touches the wall
Gait and balanceGait steady; tandem stance 8 seconds, unchanged
MouthGood dentition; no exposed bone or gum swelling

Problems

ProblemClinical statusVerificationCodeProvenance
Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 1991 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold)activeconfirmed M85.89S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture.
Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol sinceactiveconfirmed F10.21S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit.
History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls sinceactiveconfirmed Z91.81S — Synthetic modern entry linked to her publicly described falls and fractures.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySecondary-causes work-upAt diagnosis: calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calciumUp to dateAt intake: calcium 9.4 mg/dL, albumin 4.2 g/dL, phosphate 3.5, magnesium 2.0, alkaline phosphatase 84 U/L, creatinine 0.8 mg/dL (eGFR 81), PTH 54 pg/mL, TSH 1.9, hemoglobin 13.3, all normal; 25-hydroxyvitamin D 24 ng/mL, low
Laboratory24-hour urine calciumAt diagnosis, before starting therapyDeferredOrdered at intake to be collected before today; not collected because she was traveling. Deviation from the baseline work-up. No harm so far, because no drug has been started. Corrective action: container and instructions given again, and the result is required before the first infusion
Laboratory25-hydroxyvitamin DAt baseline; after repletion until 30 ng/mL or more; then yearlyDue24 ng/mL at intake; recheck at three months, before the first infusion
LaboratorySerum calcium before each intravenous antiresorptive doseBefore each zoledronic acid doseDuePlanned at three months, before the first infusion
LaboratoryBone-turnover marker (fasting serum CTX)Baseline, then 3 to 6 months after starting or changing therapyUp to date560 pg/mL at intake; repeat three months after the first dose
ImagingCentral DXA of the spine and hipEvery 1 to 2 years on therapy until stable, on the same scannerUp to dateBaseline at intake; repeat two years after starting therapy
ImagingVertebral fracture assessmentAt baseline with a recent low-trauma fracture, height loss of 4 cm or more, or a T-score of -2.5 or lowerUp to dateDone at intake for the recent low-trauma fracture: no vertebral fracture
ExaminationStanding height by stadiometerYearly; vertebral imaging again if height falls 2 cm or moreUp to date164.0 cm at intake
ExaminationFall-risk screenYearly, and with any fallUp to dateAt intake: Timed Up and Go 11 seconds, tandem stance 8 seconds, chair stand 11; fall with fracture in the past year
SurveyFRAX 10-year fracture riskAt baseline and when risk factors changeUp to date22 percent major osteoporotic and 3.6 percent hip at intake; no change in risk factors
SurveyCalcium intake assessmentAt baseline and yearlyCompleted todayAbout 1200 mg a day from food by three-day record, up from about 800 mg
Medication safetyDental examination before an antiresorptiveBefore starting a bisphosphonate or denosumabDueRoutine dental examination booked next month, before the first infusion
Medication safetyDrug-holiday eligibilityAfter 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonateNot indicatedNo drug started yet
Medication safetyDenosumab continuity checkEvery 6 months on denosumabNot indicatedNot on denosumab
ReferralEndocrinology consultationWhen the diagnosis, risk category, or drug choice needs specialist reviewCompleted todaySeen today; treatment indicated; zoledronic acid recommended after vitamin D repletion
Self-managementBalance and strength exercise programWith a history of falls or impaired balanceReferredPhysical therapist program begins next week
Self-managementRecovery check (alcohol, cravings, stress)Every visitCompleted todayNo alcohol; no cravings
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Balance program from next week. Dental examination next month. 24-hour urine collection before the next visit. Bone health review in two months with pre-infusion tests and the first infusion. Next scheduled visit 1997-05-12: three-month bone health review and first zoledronic acid infusion. [S]